Positive News SentimentPositive NewsNASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis $7.32 0.00 (0.00%) Closing price 09/4/2026 04:00 PM EasternExtended Trading$7.38 +0.05 (+0.75%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Maravai LifeSciences Stock (NASDAQ:MRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maravai LifeSciences alerts:Sign Up Key Stats Today's Range$7.17▼$7.4450-Day Range$5.68▼$9.0052-Week Range$2.37▼$9.42Volume1.55 million shsAverage Volume4.74 million shsMarket Capitalization$1.90 billionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingHold Company Overview Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry. Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. The company’s TriLink® division supplies custom nucleic acids and enzymatic reagents for RNA and DNA synthesis, while its SeraCode™ and ExoScale™ offerings provide specialized tools for protein quantification and extracellular vesicle analysis. Maravai also offers contract development and manufacturing services to support scale-up and commercialization efforts for novel biologic candidates. Founded in 2015 and headquartered in San Diego, California, Maravai has grown through strategic acquisitions and organic innovation to serve clients in North America, Europe and Asia. The company partners with leading pharmaceutical and biotechnology organizations to advance vaccine programs, cell and gene therapies and precision diagnostics. Under the leadership of President and Chief Executive Officer Brent P. Saunders, Maravai continues to invest in research and development, expanding its global manufacturing footprint and strengthening its position in high-growth markets for advanced therapies.AI Generated. May Contain Errors. Read More Maravai LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreMRVI MarketRank™: Maravai LifeSciences scored higher than 27% of companies evaluated by MarketBeat, and ranked 785th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingMaravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 2 sell ratings.Downside RiskMaravai LifeSciences has a consensus price target of $6.25, representing about 14.6% downside from its current price of $7.32.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 2 research reports in the past 90 days.Read more about Maravai LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.20) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -14.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -14.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.71% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 4.61.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 10.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment1.70 News SentimentMaravai LifeSciences has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Maravai LifeSciences this week, compared to 2 articles on an average week.Search Interest8 people have searched for MRVI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,500.00 in company stock.Percentage Held by Insiders2.49% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRVI Stock News HeadlinesMaravai LifeSciences (NASDAQ:MRVI) Lowered to Hold Rating by Wall Street ZenAugust 29, 2026 | americanbankingnews.comTEM, BNTX, MRVI, RGEN, NVAX stock rallies as Moderna-Merck cancer vaccine clears late-stage trialAugust 19, 2026 | msn.comThis sub-5 dollar stock operates next to SpaceX and Blue OriginA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, right alongside SpaceX and Blue Origin. It holds a special agreement to use a multi-billion dollar federal launch facility for just $500, and its customer list already includes the Pentagon, Lockheed Martin, and GE Aerospace. Most Wall Street analysts have not caught on yet, but a major milestone could change that soon.September 8 at 1:00 AM | Freedom Financial (Ad)Stifel Nicolaus Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)August 15, 2026 | theglobeandmail.comMaravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss NarrowsAugust 7, 2026 | quiverquant.comQMaravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comMaravai LifeSciences Reports Second Quarter 2026 Financial ResultsAugust 7, 2026 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 6, 2026 | seekingalpha.comSee More Headlines MRVI Stock Analysis - Frequently Asked Questions How have MRVI shares performed this year? Maravai LifeSciences' stock was trading at $3.25 on January 1st, 2026. Since then, MRVI shares have increased by 125.2% and is now trading at $7.32. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The business earned $51.44 million during the quarter, compared to analysts' expectations of $48.67 million. Maravai LifeSciences had a negative net margin of 37.07% and a negative trailing twelve-month return on equity of 15.70%. Read the conference call transcript. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.5 billion in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Top institutional shareholders of Maravai LifeSciences include Braidwell LP (3.35%), Bank of New York Mellon Corp (0.14%), Headlands Technologies LLC (0.06%) and Public Employees Retirement System of Ohio (0.04%). Insiders that own company stock include Gtcr Investment Xi Llc, Bernd Brust, Kurt Oreshack, Carl Hull and Gregory T Lucier. View institutional ownership trends. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Maravai LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2026Today9/07/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MRVI's financial health is in the Green zone, according to TradeSmith. MRVI has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:MRVI CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees610Year Founded2014Price Target and Rating Average Price Target for Maravai LifeSciences$6.25 High Price Target$6.50 Low Price Target$6.00 Potential Upside/Downside-14.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.77 million Net Margins-37.07% Pretax Margin-65.38% Return on Equity-15.70% Return on Assets-8.17% Debt Debt-to-Equity Ratio0.49 Current Ratio4.05 Quick Ratio2.98 Sales & Book Value Annual Sales$185.74 million Price / Sales10.23 Cash Flow$0.42 per share Price / Cash Flow17.49 Book Value$1.46 per share Price / Book5.01Miscellaneous Outstanding Shares259,670,000Free Float253,208,000Market Cap$1.90 billion OptionableOptionable Beta0.60 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MRVI) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredBuffett’s “Green New Deal” (trigger warning!)Warren Buffett's largest stock bet ever now tops 29 billion dollars, dwarfing his historic positions in Coca-C...Porter & Company | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRVI Stock Alerts